Home Featured Page 294

Featured

Latest

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

From Brussels to the Ballot: How PsychedeliCare Took Psychedelic Therapy to the European Public

Psychedelic Medicine at the Edge of Science and Spirit

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin...

How Past Stigma and Recreational Use Are Slowing Psychedelic Science

John C. Lilly: Father of LSD In the Sensory Deprivation Tank

Psyched Wellness Closes $6,603,000 Bought Deal Private Placement

Revive Therapeutics Acquires Unique Psilocybin Assets

PharmaTher Announces Sale of Psilocybin Program

Video Roundtable: The Future of Ketamine Therapy

MindMed’s LSD Neutralizer Study Begins

Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap’s...

Field Trip Health Ltd. Reports Third Fiscal Quarter 2021 Financial Results

1...293294295...306 Page 294 of 306

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

From Brussels to the Ballot: How PsychedeliCare Took Psychedelic Therapy to...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

From Brussels to the Ballot: How PsychedeliCare Took Psychedelic Therapy to the European Public

Psychedelic Medicine at the Edge of Science and Spirit

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin...

How Past Stigma and Recreational Use Are Slowing Psychedelic Science

John C. Lilly: Father of LSD In the Sensory Deprivation Tank

Psyched Wellness Closes $6,603,000 Bought Deal Private Placement

Revive Therapeutics Acquires Unique Psilocybin Assets

PharmaTher Announces Sale of Psilocybin Program

Video Roundtable: The Future of Ketamine Therapy

MindMed’s LSD Neutralizer Study Begins

MindMed’s LSD Neutralizer Study Begins

Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap’s...

Field Trip Health Ltd. Reports Third Fiscal Quarter 2021 Financial Results

EDITOR PICKS

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

From Brussels to the Ballot: How PsychedeliCare Took Psychedelic Therapy to...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY